Sustained-release 9-cis retinoic acid implantable drug delivery pellets for the prevention of postsurgical edema and lymphedema
Inventors
Wong, Alex K. • HONG, YOUNG-KWON
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A method of treating post-surgical edema includes a step of administering an effective amount of a pharmaceutical composition to a subject identified a risk of post-surgical edema. The pharmaceutic composition include a retinoic acid component selected from the group consisting of 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations thereof. An implantable pellet including the retinoic acid component is also provided.
Core Innovation
The invention relates to treating post-surgical edema by identifying a subject undergoing surgery that is at risk for edema and administering an effective amount of a pharmaceutical composition. The pharmaceutical composition includes a retinoic acid component selected from 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations. In human subjects, the retinoic acid component is administered at a dosage of 0.001 mg to 50 mg per kg of subject weight and over a time period of 15 to 90 days.
The composition is administered orally, intravenously, by implant, liposomally, intranasally, topically, rectally, by a transdermal patch, or parentally. A related embodiment specifies that the subject is at risk for post-surgical lymphedema. The compositions may additionally include diluents, excipients, and carriers, in which the retinoic acid component is present in an effective amount.
An additional core aspect is implanting an implantable pellet into the subject during or after surgery for treatment of postsurgical lymphedema. The implantable pellet includes a carrier and the retinoic acid component dispersed within the carrier in an effective amount. The carrier is at least partially biodegradable, and the carrier is described as a biodegradable matrix that effectively and continuously releases the 9-cis retinoic acid when implanted.
Claims Coverage
The independent claims cover three inventive approaches: general post-surgical edema treatment with a specified 9-cis retinoic acid component dosing regimen over 15 to 90 days, the same post-surgical edema treatment using broad administration routes and optional formulation components, and postsurgical lymphedema treatment via implantation of an implantable pellet containing a biodegradable carrier with continuous release behavior. Across these approaches, the claims identify multiple inventive features: patient selection at risk for edema, selection of the retinoic acid component, effective dosing ranges and duration windows, and formulation and administration structure including an implantable pellet and continuous release biodegradable matrix.
Identifying a subject at risk for post-surgical edema
The method includes identifying a subject undergoing surgery that is at risk for edema.
Administering a retinoic acid component selected from 9-cis retinoic acid forms
The method administers an effective amount of a pharmaceutical composition including a retinoic acid component selected from 9-cis retinoic acid, geometric isomers of 9-cis retinoic acid, metabolites of 9-cis retinoic acid, substituted derivatives thereof, and combinations thereof.
Weight-based retinoic acid dosing over 15 to 90 days
For a human subject, a dosage of the retinoic acid component is 0.001 mg to 50 mg per kg of subject weight, wherein the dosage is administered over a time period of 15 to 90 days.
Multi-route administration of the pharmaceutical composition
The pharmaceutical composition is administered orally, intravenously, by implant, liposomally, intranasally, topically, rectally, by a transdermal patch, or parentally.
Implanting an implantable pellet during or after surgery containing retinoic acid dispersed in a carrier
The pharmaceutical composition is administered by implanting an implantable pellet into the subject during or after surgery, the implantable pellet including a carrier and the retinoic acid component dispersed within the carrier in an effective amount to treat postsurgical lymphedema.
Biodegradable carrier providing effective continuous release
The carrier is at least partially biodegradable, and is described as a biodegradable matrix that effectively and continuously releases 9-cis retinoic acid when the implantable pellet is implanted in a subject.
Quantified retinoic acid release performance from the implanted pellet
At least 90 percent of the 9-cis retinoic acid is released into the subject for 60 days post implantation.
Overall, the claims cover post-surgical edema treatment using a specified retinoic acid component with an effective human dosing regimen and duration window, optionally across multiple administration routes. A further independent claim emphasizes a pellet-based embodiment in which a biodegradable carrier disperses the retinoic acid and continuously releases it after implantation, including a quantitative release threshold.
Stated Advantages
Reduces paw/tail swelling in mouse hind-limb and tail lymphedema models.
Improves lymphatic clearance, including via ICG lymphography and ICG fluorescence.
Decreases histologic markers, including epidermal hyperplasia, for example via Malpighian layer thickness.
9-cis retinoic acid has a favorable cancer-related risk profile versus VEGF-C/VEGF-D.
Documented Applications
Treating post-surgical edema, including postsurgical lymphedema, in subjects undergoing surgery identified as being at risk for edema.
Use of an implantable pellet implanted during or after surgery to treat postsurgical lymphedema.
Preclinical evaluation in mouse hind-limb and tail lymphedema models, including assessment of lymphatic clearance and histologic changes.
Interested in licensing this patent?